272 related articles for article (PubMed ID: 12559177)
21. Molecular targets from VHL studies into the oxygen-sensing pathway.
Maynard MA; Ohh M
Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
[TBL] [Abstract][Full Text] [Related]
22. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
24. The HIF pathway: implications for patterns of gene expression in cancer.
Wykoff CC; Pugh CW; Harris AL; Maxwell PH; Ratcliffe PJ
Novartis Found Symp; 2001; 240():212-25; discussion 225-31. PubMed ID: 11727931
[TBL] [Abstract][Full Text] [Related]
25. Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes.
Biju MP; Neumann AK; Bensinger SJ; Johnson RS; Turka LA; Haase VH
Mol Cell Biol; 2004 Oct; 24(20):9038-47. PubMed ID: 15456877
[TBL] [Abstract][Full Text] [Related]
26. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor.
Vaux EC; Wood SM; Cockman ME; Nicholls LG; Yeates KM; Pugh CW; Maxwell PH; Ratcliffe PJ
J Biol Chem; 2001 Nov; 276(47):44323-30. PubMed ID: 11555645
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
28. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
29. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein.
Yu F; White SB; Zhao Q; Lee FS
Cancer Res; 2001 May; 61(10):4136-42. PubMed ID: 11358837
[TBL] [Abstract][Full Text] [Related]
30. VHL takes HIF's breath away.
Krek W
Nat Cell Biol; 2000 Jul; 2(7):E121-3. PubMed ID: 10878820
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
[TBL] [Abstract][Full Text] [Related]
32. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.
Maxwell PH; Pugh CW; Ratcliffe PJ
Adv Exp Med Biol; 2001; 502():365-76. PubMed ID: 11950150
[TBL] [Abstract][Full Text] [Related]
33. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
[TBL] [Abstract][Full Text] [Related]
34. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
35. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
36. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
37. von Hippel-Lindau tumor suppressor: not only HIF's executioner.
Czyzyk-Krzeska MF; Meller J
Trends Mol Med; 2004 Apr; 10(4):146-9. PubMed ID: 15162797
[TBL] [Abstract][Full Text] [Related]
38. Von Hippel-Lindau disease: clinical and molecular perspectives.
Clifford SC; Maher ER
Adv Cancer Res; 2001; 82():85-105. PubMed ID: 11447766
[TBL] [Abstract][Full Text] [Related]
39. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Kim W; Kaelin WG
Curr Opin Genet Dev; 2003 Feb; 13(1):55-60. PubMed ID: 12573436
[TBL] [Abstract][Full Text] [Related]
40. Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors.
Blagosklonny MV
Oncogene; 2001 Jan; 20(3):395-8. PubMed ID: 11313969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
